U-CART (Shanghai Bioray Laboratory Inc)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameU-CART (Shanghai Bioray Laboratory Inc)

Drug Alias Nameanti-CD19 CAR-T cell therapy (hematological malignancy)

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Source of cells > PMBC-derivedCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulators

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsHematologic NeoplasmsPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesBRL Medicine Inc

China Registration ClassN/A

Develop Information

Active CompaniesBRL Medicine Inc

Inactive CompaniesN/A

Active IndicationsHematologic NeoplasmsPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A